![]() |
|
|
Complementary Medicine - Cam
Topic ContentsGinkgoUsesCommon names: Maidenhair Tree
Botanical names: Ginkgo biloba
Parts Used & Where GrownGinkgo biloba is the world’s oldest living species of tree. Individual trees live as long as 1,000 years. Ginkgo grows most predominantly in the southern and eastern United States, southern France, China, and Korea. The leaves of the tree are used in modern herbal medicine.
What Are Star Ratings?
Our proprietary “Star-Rating” system was developed to help you easily understand the amount of scientific support behind each supplement in relation to a specific health condition. While there is no way to predict whether a vitamin, mineral, or herb will successfully treat or prevent associated health conditions, our unique ratings tell you how well these supplements are understood by the medical community, and whether studies have found them to be effective for other people. For over a decade, our team has combed through thousands of research articles published in reputable journals. To help you make educated decisions, and to better understand controversial or confusing supplements, our medical experts have digested the science into these three easy-to-follow ratings. We hope this provides you with a helpful resource to make informed decisions towards your health and well-being. 3 Stars Reliable and relatively consistent scientific data showing a substantial health benefit. 2 Stars Contradictory, insufficient, or preliminary studies suggesting a health benefit or minimal health benefit. 1 Star For an herb, supported by traditional use but minimal or no scientific evidence. For a supplement, little scientific support. This supplement has been used in connection with the following health conditions:
Traditional Use (May Not Be Supported by Scientific Studies)Medicinal use of ginkgo can be traced back almost 5,000 years in Chinese herbal medicine. The nuts of the tree were most commonly recommended and used to treat respiratory tract ailments. The use of the leaves is a modern development originating in Europe. How It WorksCommon names: Maidenhair Tree
Botanical names: Ginkgo biloba
How It WorksThe medical benefits of Ginkgo biloba extract are attributed primarily to two groups of active constituents: the ginkgo flavone glycosides and the terpene lactones. Ginkgo flavone glycosides, which typically make up approximately 24% of the extract, are primarily responsible for ginkgo’s antioxidant activity and may mildly inhibit platelet aggregation (stickiness). These two actions may help ginkgo prevent circulatory diseases, such as atherosclerosis , and support the brain and central nervous system.59 In addition to the cardiovascular system, ginkgo’s antioxidant action may also extend to the brain and retina of the eye.60 Preliminary trials have suggested potential benefit for people with macular degeneration 61 and diabetic retinopathy .62 The terpene lactones found in ginkgo extracts, known as ginkgolides and bilobalide, typically make up approximately 6% of the extract. They are associated with increasing circulation to the brain and other parts of the body and may exert a protective action on nerve cells.63 ginkgo regulates the tone and elasticity of blood vessels,64 making circulation more efficient.65 Ginkgo is also well-known for its effect on memory and thinking (cognitive function). It may enhance cognitive performance in healthy older adults,66 in people with age-related cognitive decline , and in people with Alzheimer’s disease . How to Use ItMost clinical trials have used between 120 and 240 mg of ginkgo (standardized to contain 6% terpene lactones and 24% flavone glycosides) per day, generally divided into two or three portions.67 The higher amount (240 mg per day) has been used in some people with mild-to-moderate Alzheimer’s disease , age-related cognitive decline , intermittent claudication , and resistant depression . Ginkgo may need to be taken for eight to twelve weeks before desired actions such as cognitive improvement are noticed. Although nonstandardized Ginkgo biloba leaf and tinctures are available, there is no well-established amount or use for these forms. InteractionsCommon names: Maidenhair Tree
Botanical names: Ginkgo biloba
Interactions with Supplements, Foods, & Other CompoundsAt the time of writing, there were no well-known supplement or food interactions with this supplement.
Interactions with MedicinesCertain medicines interact with this supplement.
Types of interactions:
Beneficial
Adverse
Check
Replenish Depleted Nutrients
Reduce Side Effects
Support Medicine
Reduces Effectiveness
Potential Negative Interaction
Explanation Required
The Drug-Nutrient Interactions table may not include every possible interaction. Taking medicines with meals, on an empty stomach, or with alcohol may influence their effects. For details, refer to the manufacturers’ package information as these are not covered in this table. If you take medications, always discuss the potential risks and benefits of adding a supplement with your doctor or pharmacist.
Side EffectsCommon names: Maidenhair Tree
Botanical names: Ginkgo biloba
Side EffectsExcessive bleeding has been reported in a few individuals taking ginkgo,113 , 114 although a cause/effect relationship was not proven. A review of 18 randomized controlled trials with a total of 1,985 adults concluded that it is unlikely that taking ginkgo increases the risk of bleeding.115 In addition, two elderly individuals with well-controlled epilepsy developed recurrent seizures within two weeks after starting ginkgo.116 Mild headaches lasting for a day or two and mild upset stomach have been reported in a small number of people using ginkgo. Ginkgo leaves are known to contain a group of potentially toxic constituents known as alkylphenols. To reduce the potential for adverse effects, the German Commission E Monograph requires that ginkgo products for human consumption contain less than 5 parts per million of alkylphenols.117 One small clinical trial found that ginkgo supplementation for three months increased secretion of insulin by the pancreas, but did not affect blood glucose levels, in healthy young adults.118 These results suggest that the participants may have developed an insensitivity to insulin, a potential concern because insulin insensitivity may be a precursor to type 2 diabetes . However, this trial does not prove that ginkgo causes insulin insensitivity, nor does it prove that long-term ginkgo supplementation increases the risk for any disease. In addition, the results of this trial are not consistent with other research on ginkgo. Larger and more rigorously designed clinical trials of ginkgo supplementation have found no significant adverse effects after as many as 12 months of supplementation.119 People should seek an accurate medical diagnosis prior to self-prescribing ginkgo. This is especially important for the elderly, whose circulatory conditions can involve serious disease, and for people scheduled for surgery, as ginkgo may affect bleeding time. Related Information
References1. Allain H, Raoul P, Lieury A, et al. Effects of two doses of ginkgo biloba extract (EGb 761) on the dual-coding test in elderly subjects. Clin Ther 1993;15(3):549–58. 2. Rai GS, Shovlin C, Wesnes KA. A double-blind, placebo-controlled study of Ginkgo biloba extract (‘tanakan’) in elderly patients with mild to moderate memory impairment. Curr Med Res Opin 1991;12(6):350–5. 3. Brautigam MRH, Blommaert FA, Verleye G, et al. Treatment of age-related memory complaints with Ginkgo biloba extract: a randomized double-blind placebo-controlled study. Phytomedicine 1998;5:425–34. 4. Wesnes K, Simmons D, Rook M. A double-blind, placebo-controlled trial of Tanakan in the treatment of idiopathic impairment in the elderly. Human Psychopharmacol 1987;2:159–69. 5. Israel L, Dell’Accio E, Martin G, Hugonot R. Ginkgo biloba extract and memory training programs—comparative assessment on elderly outpatients. Psychologie Médicale 1987;19:1431–9. 6. Gräbel E. The influence of Ginkgo biloba extract (EGb 761) on mental performance: A double-blind study under computerized measurement conditions in patients with cerebral insufficiency. Fortschr Med 1992;110:73–6. 7. Winther K, Randlov C, Rein E, Mehlsen J. Effects of Ginkgo biloba extract on cognitive function and blood pressure in elderly subjects. Curr Ther Res 1998;59:881–8. 8. Van Dongen M, van Rossum E, Kessels AGH, et al. The efficacy of ginkgo for elderly people with dementia and age-associated memory impairment: New results of a randomized clinical trial. J Am Geriatr Soc 2000;48:1183–94. 9. Le Bars PL, Katz MM, Berman N, et al. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA 1997;278:1327–32. 10. Hofferberth B. The efficacy of EGb 761 in patients with senile dementia of the Alzheimer type, a double-blind, placebo-controlled study on different levels of investigation. Hum Psychopharmacol 1994;9:215–22. 11. Kanowski S, Herrmann W, Stephan K, et al. Proof of efficacy of the Ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry 1996;29:47–56. 12. Maurer K, Ihl R, Dierks T, Frolich L. Clinical efficacy of Ginkgo biloba special extract EGb 761 in dementia of the Alzheimer’s type. J Psychiatr Res 1997;31:645–55. 13. Bachinskaya N, Hoerr R, Ihl R. Alleviating neuropsychiatric symptoms in dementia: the effects of Ginkgo biloba extract EGb 761. Findings from a randomized controlled trial. Neuropsychiatr Dis Treat 2011;7:209–15. 14. Mazza M, Capuano A, Bria P, Mazza S. Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study. Eur J Neurol 2006;13:981–5. 15. van Dongen M, van Rossum E, Kessels A, et al. The efficacy of ginkgo for elderly people with dementia and age-associated memory impairment: New results of a randomized clinical trial. J Am Geriatr Soc 2000;48:1183–94. 16. Wettstein A. Cholinesterase inhibitors and Ginkgo extracts–are they comparable in the treatment of dementia? Comparison of published placebo-controlled efficacy studies of at least six months’ duration. Phytomedicine 2000;6:393–401. 17. DeKosky ST, Williamson JD, Fitzpatrick AL, et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA 2008;300:2253–62. 18. Quaranta L, Bettelli S, Uva MG, et al. Effect of Ginkgo biloba extract on preexisting visual field damage in normal tension glaucoma. Ophthalmology 2003;110:359–62. 19. Schneider B. Ginkgo biloba extract in peripheral arterial disease. Meta-analysis of controlled clinical trials. Arzneimittelforschung 1992;42:428–36 [in German]. 20. Peters H, Kieser M, Hölscher U. Demonstration of the efficacy of Ginkgo biloba special extract EGb 761® on intermittent claudication—a placebo-controlled, double-blind multicenter trial. VASA 1998;27:106–10. 21. Bauer U. Six-month double-blind randomised clinical trial of Ginkgo biloba extract versus placebo in two parallel groups in patients suffering from peripheral arterial insufficiency. Arzneimittelforsschung 1984;34:716–20 [in German]. 22. Blume J, Kieser M, Hölscher U. Placebo-controlled, double-blind study on the efficacy of Ginkgo biloba special extract EGb 761 in maximum-level trained patients with intermittent claudication. Vasa 1996;25:265–74. 23. Blume J, Kieser M, Hölscher U. Efficacy of Ginkgo biloba special extract EGb 761 in peripheral occlusive disease. Fortschr Med 1998;116:137–43. 24. Schweizer J, Hautmann C. Comparison of two dosages of Ginkgo biloba extract EGb 761 in patients with peripheral arterial occlusive disease Fontaine’s stage IIb. Arzneimittelforschung 1999;49:900–4. 25. Wang J, Zhou S, Bronks R, et al. Supervised exercise training combined with ginkgo biloba treatment for patients with peripheral arterial disease. .Clin Rehabil 2007;21:579–86. 26. Schubert H, Halama P. Depressive episode primarily unresponsive to therapy in elderly patients; efficacy of Ginkgo biloba extract (EGb 761) in combination with antidepressants. Geriatr Forsch 1993;3:45–53. 27. Cohen AJ, Bartlik B. Ginkgo biloba for antidepressant-induced sexual dysfunction. J Sex Marital Therapy 1998;24:139–45. 28. Sohn M, Sikora R. Ginkgo biloba extract in the therapy of erectile dysfunction. J Sec Educ Ther 1991;17:53–61. 29. Cohen AJ, Bartlik B. Ginkgo biloba for antidepressant-induced sexual dysfunction. J Sex Marital Ther 1998;24:139–43. 30. Lebuisson DA, Leroy L, Reigal G. Treatment of senile macular degeneration with Ginkgo biloba extract: a preliminary double-blind study versus placebo. In Rokan (Ginkgo biloba): Recent Results in Pharmacology and Clinic, Fünfgeld FW, ed. Berlin: Springer-Verlag, 1988, 231–6. 31. Vorberg G. Ginkgo biloba extract (GBE): A long-term study of cerebral insufficiency in geriatric patients. Clin Trials J 1985;22:149–57. 32. Claussen CF. Diagnostic and practical values of craniocorpography in vertiginous syndromes. Presse Med 1986;15:1565–8 [in French]. 33. Haguenauer JP, Cantenot F, Koskas H, Pierart H. Treatment of disturbances of equilibrium with Ginkgo biloba extract: A multicenter, double-blind, drug versus placebo study. Presse Med 1986;15:1569–72 [in French]. 34. Parsad D, Pandhi R, Juneja A. Effectiveness of oral Ginkgo biloba in treating limited, slowly spreading vitiligo. Clin Exp Dermatol 2003;28:285–7. 35. Szczurko O, Shear N, Taddio A, Boon H. Ginkgo biloba for the treatment of vitilgo vulgaris: an open label pilot clinical trial. BMC Complement Altern Med 2011;11:21. 36. Guinot P, Brambilla C, Dunchier J, et al. Effect of BN 52063, a specific PAF-ascether antagonist, on bronchial provocation test to allergens in asthmatic patients—a preliminary study. Prostaglandins 1987;34:723–31. 37. Li M, Yang B, Yu H, Zhang H. Clinical observation of the therapeutic effect of ginkgo leaf concentrated oral liquor on bronchial asthma. Chinese J Integrative & Western Med 1997;3:264–7. 38. Braquet P, Touqui L, Shen TS, Vargaftig BB. Perspectives in platelet activating factor research. Pharmacol Rev 1987;39:97–210. 39. Brown DJ. Herbal Prescriptions for Better Health. Rocklin, CA: Prima Publishing, 1996, 119–28. 40. Kiesewetter H, Jung F, Mrowietz C, et al. Effects of garlic on blood fluidity and fibrinolytic activity: A randomised, placebo-controlled, double-blind study. Br J Clin Pract Suppl 1990;69:24–9. 41. Jung F, Mrowietz C, Kiesewetter H, Wenzel E. Effect of Ginkgo biloba on fluidity of blood and peripheral microcirculation in volunteers. Arzneimittelforschung 1990;40:589–93. 42. Phelps S, Harris WS. Garlic supplementation and lipoprotein oxidation susceptibility. Lipids 1993;28(5):475–7. 43. Yan LJ, Droy-Lefaix MT, Packer L. Ginkgo biloba extract (EGb 761) protects human low density lipoproteins against oxidative modification mediated by copper. Biochem Biophys Res Comm 1995;212:360–6. 44. Singh K, Chander R, Kapoor NK. Guggulsterone, a potent hypolipidaemic, prevents oxidation of low density lipoprotein. Phytother Res 1997;11:291–4. 45. Clostre F. Ginkgo biloba extract (EGb 761). State of knowledge in the dawn of the year 2000. Ann Pharm Fr 1999 ;57:1S8–88 [review; in French]. 46. Chung KF, McCusker M, Page CP, et al. Effect of a ginkgolide mixture (BN 52063) in antagonising skin and platelet responses to platelet activating factor in man. Lancet 1987;i:248–51. 47. Brochet B, Orgogozo JM, Guinot P, et al. Pilot study of Ginkgolide B, a PAF-acether specific inhibitor in the treatment of acute outbreaks of multiple sclerosis. Rev Neurol (Paris) 1992;148:299–301 [in French]. 48. Tamborini A, Taurelle R. Value of standardized Ginkgo biloba extract (EGb 761) in the management of congestive symptoms of premenstrual syndrome. Rev Fr Gynecol Obstet 1993;88:447–57 [in French]. 49. Kleijnen J, Knipschild P. Ginkgo biloba. Lancet 1992;340:1136–9 [review]. 50. Clement JL, Livecchi G, Jimenez C, et al. Modifications vasomotrices des extrémités lors l’exposition à des conditions thermiques défavorables. Méthodologie et résultant de l’étude de l’extrait de Ginkgo biloba. Acutal Angiol 1982;7:3–8. 51. Lanthony P, Cosson JP. The course of color vision in early diabetic retinopathy treated with Ginkgo biloba extract. A preliminary double-blind versus placebo study. J Fr Ophtalmol 1988;11:671–4 [in French]. 52. Ernst E, Stevinson C. Ginkgo biloba for tinnitus: a review. Clin Otolaryngol 1999;24:164–7. 53. Drew S, Davies E. Effectiveness of Ginkgo biloba in treating tinnitus: double blind, placebo-controlled trial. BMJ 2001;322:1–6. 54. Meyer B. A multicenter randomized double-blind study of Ginkgo biloba extract versus placebo in the treatment of tinnitus. In Rokan (Ginkgo biloba): Recent Results in Pharmacology and Clinic, ed. EW Funfgeld. New York: Springer-Verlag, 1988, 245–50. 55. Morgenstern C, Biermann E. Ginkgo biloba special extract EGb 761 in the treatment of tinnitus aurium: Results of a randomized, double-blind, placebo-controlled study. Fortschr Med 1997;115:7–11. 56. Holgers K, Axelsson A, Pringle I. Ginkgo biloba extract from the treatment of tinnitus. Audiol 1994;33:85–92. 57. Koltringer P, Langsteger W, Lind P, et al. [Ginkgo biloba extract and folic acid in the therapy of changes caused by autonomic neuropathy]. Acta Med Austriaca 1989;16:35–7 [in German]. 58. Koltringer P, Langsteger W, Lind P, et al. [Ginkgo biloba extract and folic acid in the therapy of changes caused by autonomic neuropathy]. Acta Med Austriaca 1989;16:35–7 [in German]. 59. Drieu K. Preparation and definition of Ginkgo biloba extract. In: Rokan (Ginkgo biloba): Recent Results in Pharmacology and Clinic. Fünfgeld EW, ed. Berlin: Springer-Verlag, 32–6. 60. Ferrandini C, Droy-Lefaix MT, Christen Y, eds. Ginkgo biloba Extract (EGb 761) as a Free Radical Scavenger. Paris: Elsevier, 1993. 61. Lebuisson DA, Leroy L, Rigal G. Treatment of senile macular degeneration with Ginkgo biloba extract. A preliminary double-blind, drug versus placebo study. Presse Med 1986;15:1556–8 [in French]. 62. Lanthony P, Cosson JP. Evolution of color vision in diabetic retinopathy treated by extract of Ginkgo biloba. J Fr Ophthalmol 1988;11:671–4 [in French]. 63. Krieglstein J. Neuroprotective properties of Ginkgo biloba—constituents. Zeitschrift Phytother 1994;15:92–6. 64. Clostre F. From the body to the cell membranes: the different levels of pharmacological action of Ginkgo biloba extract. In: Rokan (Ginkgo biloba): Recent Results in Pharmacology and Clinic.Fünfgeld EW, ed. Berlin: Springer-Verlag, 1988, 180–98. 65. Jung F, Mrowietz C, Kiesewetter H, Wenzel E. Effect of Ginkgo biloba on fluidity of blood and peripheral microcirculation in volunteers. Arzneimittelforschung 1990;40:589–93. 66. Mix JA, Crews WD. An examination of the efficacy of Ginkgo biloba extract EGb761 on the neuropsychologic functioning of cognitively intact older adults. J Altern Complement Med 2000;6:219–29. 67. Blumenthal M, Busse WR, Goldberg A, et al, eds. The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines. Boston, MA: Integrative Medicine Communications, 1998, 136–8. 68. Cohen AJ, Bartlik B. Ginkgo biloba for antidepressant-induced sexual dysfunction. J Sex Marital Therapy 1998;24:139–45. 69. Ellison JM, DeLuca P. Fluoxetine-induced genital anesthesia relieved by Ginkgo biloba extract. J Clin Psychiatry 1998;59:199–200. 70. Doruk A, Uzun O, Ozsahin A. A placebo-controlled study of extract of ginkgo biloba added to clozapine in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol 2008;23:223-7 71. Barth SA, Inselmann G, Engemann R, Heidemann HT. Influences of Ginkgo biloba on cyclosporine A included lipid peroxidation in human liver microsomes in comparison to vitamin E, glutathione and N-acetylcysteine. Biochem Pharmacol 1991;41:1521–6. 72. Bagnis C, Deray G, Dubois M, et al. Prevention of cyclosporine nephrotoxicity with a platelet-activating factor (PAF) antagonist. Nephrol Dial Transplant 1996;11:507–13. 73. Cohen AJ, Bartlik B. Ginkgo biloba for antidepressant-induced sexual dysfunction. J Sex Marital Ther 1998;24:139–45. 74. Ellison JM, DeLuca P. Fluoxetine-induced genital anesthesia relieved by Ginkgo biloba extract. J Clin Psychiatry 1998;59:199–200. 75. Cohen AJ, Bartlik B. Ginkgo biloba for antidepressant-induced sexual dysfunction. J Sex Marital Ther 1998;24:139–45. 76. Ellison JM, DeLuca P. Fluoxetine-induced genital anesthesia relieved by Ginkgo biloba extract. J Clin Psychiatry 1998;59:199–200. 77. Zhang XY, Zhou DF, Zhang PY, et al. A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia. J Clin Psychiatry 2001;62:878–83. 78. Cohen AJ. Long term safety and efficacy of Ginkgo biloba extract in the treatment of anti-depressant-induced sexual dysfunction. Psychiatry On-Line http://www.priory.com/ginkgo.html. 79. Sohn M, Sikora R. Ginkgo biloba extract in the therapy of erectile dysfunction. J Sex Educ Ther 1991;17:53–61. 80. Cohen AJ. Long term safety and efficacy of Ginkgo biloba extract in the treatment of anti-depressant-induced sexual dysfunction. Psychiatry On-Line http://www.priory.com/ginkgo.html. 81. Sohn M, Sikora R. Ginkgo biloba extract in the therapy of erectile dysfunction. J Sex Educ Ther 1991;17:53–61. 82. Matthews MK. Association of Ginkgo biloba with intracerebral hemorrhage [letter]. Neurology 1998;50:1933. 83. Rosenblatt M, Mindell J. Spontaneous hyphema associated with ingestion of Ginkgo biloba extract [letter]. N Engl J Med 1997;336:1108. 84. Shaw D et al. Traditional remedies and food supplements: a 5-year toxicological study (1991–1995). Drug Safety 1997;17:342–56. 85. Shaw D et al. Traditional remedies and food supplements: a 5-year toxicological study (1991–1995). Drug Safety 1997;17:342–56. 86. Shaw D et al. Traditional remedies and food supplements: a 5-year toxicological study (1991–1995). Drug Safety 1997;17:342–56. 87. Kudolo GB. The effect of 3-month ingestion of Ginkgo biloba extract (EGb 761) on pancreatic beta-cell function in response to glucose loading in individuals with non-insulin-dependent diabetes mellitus. J Clin Pharmacol2001;41:600–11. 88. Kudolo GB. The effect of 3-month ingestion of Ginkgo biloba extract (EGb 761) on pancreatic beta-cell function in response to glucose loading in individuals with non-insulin-dependent diabetes mellitus. J Clin Pharmacol 2001;41:600–11. 89. Kudolo GB. The effect of 3-month ingestion of Ginkgo biloba extract (EGb 761) on pancreatic beta-cell function in response to glucose loading in individuals with non-insulin-dependent diabetes mellitus. J Clin Pharmacol 2001;41:600–11. 90. Kleijnen J, Knipschild P. Ginkgo biloba. Lancet 1992;340:1136–9. 91. Rosenblatt M, Mindel J. Spontaneous hyphema associated with ingestion of Ginkgo biloba in whom bleeding occurred after the addition of ginkgo. 92. Mathews MK. Association of Ginkgo biloba with intracerebral hemorrhage. Neurology 1998;50:1934. 93. Shaw D et al. Traditional remedies and food supplements: a 5-year toxicological study (1991–1995). Drug Safety 1997;17:342–56. 94. Shaw D et al. Traditional remedies and food supplements: a 5-year toxicological study (1991–1995). Drug Safety 1997;17:342–56. 95. Kellermann AJ, Kloft C. Is there a risk of bleeding associated with standardized Ginkgo biloba extract therapy? A systematic review and meta-analysis. Pharmacotherapy 2011;31:490-502. 96. Shaw D et al. Traditional remedies and food supplements: a 5-year toxicological study (1991–1995). Drug Safety 1997;17:342–56. 97. Kudolo GB. The effect of 3-month ingestion of Ginkgo biloba extract (EGb 761) on pancreatic beta-cell function in response to glucose loading in individuals with non-insulin-dependent diabetes mellitus. J Clin Pharmacol 2001;41:600–11. 98. Shaw D et al. Traditional remedies and food supplements: a 5-year toxicological study (1991–1995). Drug Safety 1997;17:342–56. 99. Shaw D et al. Traditional remedies and food supplements: a 5-year toxicological study (1991–1995). Drug Safety 1997;17:342–56. 100. Shaw D et al. Traditional remedies and food supplements: a 5-year toxicological study (1991–1995). Drug Safety 1997;17:342–56. 101. Kudolo GB. The effect of 3-month ingestion of Ginkgo biloba extract (EGb 761) on pancreatic beta-cell function in response to glucose loading in individuals with non-insulin-dependent diabetes mellitus. J Clin Pharmacol 2001;41:600–11. 102. Kleijnen J, Knipschild P. Ginkgo biloba. Lancet 1992;340:1136–9. 103. Kim YS, Pyo MK, Park KM. Antiplatelet and antithrombotic effects of a combination of ticlopidine and Ginkgo biloba ext (EGb 761). Thromb Res 1998;91:33–8. 104. Rosenblatt M, Mindel J. Spontaneous hyphema associated with ingestion of Ginkgo biloba extract. N Engl J Med 1997;336:1108. 105. Rowin J, Lewis SL. Spontaneous bilateral subdural hematoma with chronic Ginkgo biloba ingestion. Neurology 1996;46:1775–6. 106. Galluzzi S, Zanetti O, Binetti G, et al. Coma in a patient with Alzheimer’s disease taking low dose trazodone and Ginkgo biloba. J Neurol Neurosurg Psychiatry 2000;68:679–80. 107. Shaw D et al. Traditional remedies and food supplements: a 5-year toxicological study (1991–1995). Drug Safety 1997;17:342–56. 108. Kleijnen J, Knipschild P. Ginkgo biloba. Lancet 1992;340:1136–9. 109. Rosenblatt M, Mindel J. Spontaneous hyphema associated with ingestion of Ginkgo biloba extract. N Engl J Med 1997;336:1108. 110. Rowin J, Lewis SL. Spontaneous bilateral subdural hematoma with chronic Ginkgo biloba ingestion. Neurology 1996;46:1775–6. 111. Mathews MK. Association of Ginkgo biloba with intracerebral hemorrhage. Neurology 1998;50:1934. 112. Gilbert GJ. Ginkgo biloba. Lancet 1997;1137 [letter]. 113. Matthews MK Jr. Association of Ginkgo biloba with intracerebral hemorrhage. Neurology 1998;50:1933–4 [letter]. 114. Rosenblatt M, Mindel J. Spontaneous hyphema associated with ingestion of Ginkgo biloba extract. N Engl J Med 1997;336:1108 [letter]. 115. Kellermann AJ, Kloft C. Is there a risk of bleeding associated with standardized Ginkgo biloba extract therapy? A systematic review and meta-analysis. Pharmacotherapy 2011;31:490–502 116. Granger AS. Ginkgo biloba precipitating epileptic seizures. Age Ageing 2001;30:523–5. 117. Siegers CP. Cytotoxicity of alkylphenols from Ginkgo biloba. Phytomedicine 1999;6:281–3. 118. Kudolo GB. The effect of 3-month ingestion of Ginkgo biloba extract on pancreatic ß-cell function in response to glucose loading in normal glucose-tolerant individuals. J Clin Pharmacol 2000;40:647–54. 119. Le Bars PL, Katz MM, Berman N, et al. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA 1997;278:1327–32.
Last Review: 11-07-2012 Copyright © 2012 Aisle7. All rights reserved. Aisle7.com Learn more about Aisle7, the company. The information presented in Aisle7 is for informational purposes only. It is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over the counter medication is also available. Consult your doctor, practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications. Information expires June 2013. This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||



